June 2017 | Targeted Therapies in Oncology

The Choice Between Immunotherapy and TKIs for Liver Cancer

June 20, 2017

Clinical Articles

Options for treating patients with hepatocellular carcinoma may currently be limited, with most physicians turning to a tyrosine kinase inhibitor for advanced disease, but physicians may soon be able to choose between a TKI and immunotherapy.

The Rapid Uptake of Immunotherapy in Bladder Cancer

June 16, 2017

Clinical Articles

Immunotherapy agents have been rapidly absorbed into the treatment paradigm for various cancer types. Nowhere is this more obvious than in the treatment for patients with bladder cancer. In May alone, 3 checkpoint inhibitors were approved for use in bladder cancer, bringing the total of checkpoint inhibitors approved in this field to 5 agents.